Also Known As: Ropinirole, Requip, Ropark, Adartrel

Ropinirole (INN; trade names Requip, Ropark, Adartrel) is a non-ergoline dopamine agonist. It is manufactured by GlaxoSmithKline (GSK), Cipla and Sun Pharmaceutical. It is used in the treatment of Parkinson's disease. Ropinirole is one of three medications approved by the FDA to treat Restless Legs Syndrome, the other two being pramipexole (Mirapex) and gabapentin enacarbil (Horizant). The discovery of the drug's utility in RLS has been used as a successful example of drug repurposing.

Ropinirole's patent expired in May 2008, and the drug is now available in generic form.

Ropinirole is prescribed for mainly Parkinson's disease, restless leg syndrome, and extrapyramidal symptoms. It can also reduce the side effects caused by selective serotonin reuptake inhibitors, including Parkinsonism syndrome as well as sexual dysfunction and erectile dysfunction caused by either SSRIs or antipsychotics.

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Complete a survey on Ropinirole to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.